An ongoing dialogue on HIV/AIDS, infectious diseases,
January 20th, 2011
A New Antiretroviral Drug Class, and a Movie
In my email in-box today was a very odd press release, referring to this paper, just published in PLoS ONE. With the subject line, “Koronis – Clinical Trial Results Demonstrate Promise for First Non-suppressive HIV Drug,” it included the following information:
Recently published Phase 2a clinical trial results show that the frequency of specific, drug-induced mutations in the HIV genome can be significantly increased by administering KP-1461, a drug being developed by Koronis Pharmaceuticals based on its novel Viral Decay Acceleration (VDA) drug mechanism. Koronis is planning a follow-on Phase 2 trial to determine the treatment duration required to achieve a clinically meaningful decrease in a patient’s viral load.
First, you don’t want to be known as a “Non-suppressive HIV drug.” And second, while I get the premise that giving a drug that leads to mutations probably indicates some sort of selection pressure, it’s a long way from this observation to an actual antiviral agent.
But who knows? This may be the next great antiviral drug class, and the phrase “Viral Decay Acceleration” — with its faint echo of 1950s sci-fi movies — sounds incredibly cool. According to the company’s web site, VDA “exploits the strength of a virus – its high mutation rate – to target its collapse.”
So dim the lights, grab some popcorn, and watch the movie here.
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
FROM NEJM — Recent Infectious Disease Articles- Interactive Perspective: Measles December 18, 2025This Double Take video reviews evidence-based recommendations on measles prevention and management and explores commonly asked questions about the measles virus and infection.
- Noninferiority of One HPV Vaccine Dose to Two Doses December 18, 2025In this trial, one dose of an HPV vaccine was noninferior to two doses in preventing HPV type 16 or 18 infection.
- From Crisis to Action — Policy Pathways to Reverse the Rise in Congenital Syphilis December 18, 2025In recent years, cases of congenital syphilis have surged. This trend reflects both prenatal care gaps and systemic issues, including failures in testing, treatment, and public health infrastructure.
- Contact Precautions for MRSA and Vancomycin-Resistant Enterococcus December 18, 2025This feature about the use of contact precautions in the hospital for patients with MRSA or VRE offers a case vignette accompanied by two essays, one supporting continuing the use of contact precautions and the other recommending discontinuing them.
- Evidence to Action — Single-Dose HPV Vaccination and Cervical HPV Infection December 18, 2025Kreimer and colleagues now report in the Journal1 the results of the ESCUDDO trial, which showed that the efficacy of a single dose of either a bivalent human papillomavirus (HPV) vaccine or a nonavalent formulation was similar to that of the standard two-dose schedule. This randomized trial...
- Interactive Perspective: Measles December 18, 2025